Microbial delivery vehicles for allergens and allergen-derived peptides in immunotherapy of allergic diseases

Frontiers in Microbiology

Volumn 9, Issue JUL, 2018, Pages

  Zahirović, Abida ^a   Lunder, Mojca ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Allergy immunotherapy; Bacteriophage; Delivery vehicle; Lactic acid bacteria; S layers; Viral surface protein; Virus like particle

Indexed keywords

ALLERGEN; BINDING PROTEIN; HEMAGGLUTININ; MEMBRANE PROTEIN;

ALLERGIC DISEASE; AVIAN INFLUENZA VIRUS; BACTERIOPHAGE; FOOD ALLERGY; HEPATITIS B VIRUS; HUMAN RHINOVIRUS; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOTHERAPY; MUCOSAL DRUG ADMINISTRATION; NONHUMAN; PATHOGENICITY; RESPIRATORY TRACT ALLERGY; REVIEW;

EID: 85049403598     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2018.01449     Document Type: Review

References (105)

1. Adel-Patient, K., Ah-Leung, S., Creminon, C., Nouaille, S., Chatel, J. M., Langella, P., et al. (2005). Oral administration of recombinant Lactococcus lactis expressing bovine beta-lactoglobulin partially prevents mice from sensitization. Clin. Exp. Allergy 35, 539-546. doi: 10.1111/j.1365-2222.2005.02225.x
2. Adhya, S., Merril, C. R., and Biswas, B. (2014). Therapeutic and prophylactic applications of bacteriophage components in modern medicine. Cold Spring Harb. Perspect. Med. 4:a012518. doi: 10.1101/cshperspect.a012518
3. Aghebati-Maleki, L., Bakhshinejad, B., Baradaran, B., Motallebnezhad, M., Aghebati-Maleki, A., Nickho, H., et al. (2016). Phage display as a promising approach for vaccine development. J. Biomed. Sci. 23:66. doi: 10.1186/s12929-016-0285-9
4. Ai, C., Zhang, Q., Ding, J., Wang, G., Liu, X., Tian, F., et al. (2015a). Mucosal delivery of allergen peptides expressed by Lactococcus lactis inhibit allergic responses in a BALB/c mouse model. Appl. Microbiol. Biotechnol. 100, 1915-1924. doi: 10.1007/s00253-015-7187-8
5. Ai, C., Zhang, Q., Ren, C., Wang, G., Liu, X., Tian, F., et al. (2015b). Protective effect of Streptococcus thermophilus CCFM218 against house dust mite allergy in a mouse model. Food Control 50, 283-290. doi: 10.1016/j.foodcont.2014.08.040
6. Akdis, M., and Akdis, C. A. (2014). Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens. J. Allergy Clin. Immunol. 133, 621-631. doi: 10.1016/j.jaci.2013.12.1088
7. Anzengruber, J., Bublin, M., Bönisch, E., Janesch, B., Tscheppe, A., Braun, M. L., et al. (2017). Lactobacillus buchneri S-layer as carrier for an Ara h 2-derived peptide for peanut allergen-specific immunotherapy. Mol. Immunol. 85, 81-88. doi: 10.1016/j.molimm.2017.02.005
8. Bakhshinejad, B., and Sadeghizadeh, M. (2014). Bacteriophages as vehicles for gene delivery into mammalian cells: prospects and problems. Expert Opin. Drug Deliv. 11, 1561-1574. doi: 10.1517/17425247.2014.927437
9. Banerjee, S., Weber, M., Blatt, K., Swoboda, I., Focke-Tejkl, M., Valent, P., et al. (2014). Conversion of Der p 23, a new major house dust mite allergen, into a hypoallergenic vaccine. J. Immunol. 192, 4867-4875. doi: 10.4049/jimmunol.1400064
10. Bazan, J., Calkosinski, I., and Gamian, A. (2012). Phage display-a powerful technique for immunotherapy: 2. Vaccine delivery. Hum. Vaccin. Immunother. 8, 1829-1835. doi: 10.4161/hv.21704
11. Berlec, A., Ravnikar, M., and Strukelj, B. (2012). Lactic acid bacteria as oral delivery systems for biomolecules. Pharmazie 67, 891-898. doi: 10.1691/ph.2012.1705
12. Breitwieser, A., Egelseer, E. M., Moll, D., Ilk, N., Hotzy, C., Bohle, B., et al. (2002). A recombinant bacterial cell surface (S-layer)-major birch pollen allergen-fusion protein (rSbsC/Bet v1) maintains the ability to self-assemble into regularly structured monomolecular lattices and the functionality of the allergen. Protein Eng. 15, 243-249. doi: 10.1093/protein/15.3.243
13. Brown, S. D., Fiedler, J. D., and Finn, M. G. (2009). Assembly of hybrid bacteriophage Qbeta virus-like particles. Biochemistry 48, 11155-11157. doi: 10.1021/bi901306p
14. Bruttin, A., and Brussow, H. (2005). Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob. Agents Chemother. 49, 2874-2878. doi: 10.1128/AAC.49.7.2874-2878.2005
15. Chapot-Chartier, M.-P., Vinogradov, E., Sadovskaya, I., Andre, G., Mistou, M.-Y., Trieu-Cuot, P., et al. (2010). Cell surface of Lactococcus lactis is covered by a protective polysaccharide pellicle. J. Biol. Chem. 285, 10464-10471. doi: 10.1074/jbc. M109.082958
16. Charng, Y., Lin, C., and Hsu, C. (2006). Inhibition of allergen-induced airway inflammation and hyperreactivity by recombinant lactic-acid bacteria. Vaccine 24, 5931-5936. doi: 10.1016/j.vaccine.2005.07.107
17. Chen, X., and Dreskin, S. C. (2017). Application of phage peptide display technology for the study of food allergen epitopes. Mol. Nutr. Food Res. 61:1600568. doi: 10.1002/mnfr.201600568
18. Chesné, J., Schmidt-Weber, C. B., and Esser von-Bieren, J. (2016). The use of adjuvants for enhancing allergen immunotherapy efficacy. Immunol. Allergy Clin. North Am. 36, 125-145. doi: 10.1016/j.iac.2015.08.009
19. Clark, J. R., and March, J. B. (2014). Bacterial viruses as human vaccines? Expert Rev. Vaccin. 3, 463-476. doi: 10.1586/14760584.3.4.463
20. Colavecchio, A., Cadieux, B., Lo, A., and Goodridge, L. D. (2017). Bacteriophages contribute to the spread of antibiotic resistance genes among foodborne pathogens of the Enterobacteriaceae family-a review. Front. Microbiol. 8:1108. doi: 10.3389/fmicb.2017.01108
21. Costa, D. J., Marteau, P., Amouyal, M., Poulsen, L. K., Hamelmann, E., Cazaubiel, M., et al. (2014). Efficacy and safety of the probiotic Lactobacillus paracasei LP-33 in allergic rhinitis: a double-blind, randomized, placebo-controlled trial (GA2LEN Study). Eur. J. Clin. Nutr. 68, 602-607. doi: 10.1038/ejcn.2014.13
22. Daniel, C., Repa, A., Mercenier, A., Wiedermann, U., and Wells, J. (2007). The European LABDEL project and its relevance to the prevention and treatment of allergies. Allergy 62, 1237-1242. doi: 10.1111/j.1398-9995.2007.01496.x
23. Daniel, C., Repa, A., Wild, C., Pollak, A., Pot, B., Breiteneder, H., et al. (2006). Modulation of allergic immune responses by mucosal application of recombinant lactic acid bacteria producing the major birch pollen allergen Bet v 1. Allergy 61, 812-819. doi: 10.1111/j.1398-9995.2006.01071.x
24. Delmastro, P., Meola, A., Monaci, P., Cortese, R., and Galfre, G. (1997). Immunogenicity of filamentous phage displaying peptide mimotopes after oral administration. Vaccine 15, 1276-1285. doi: 10.1016/S0264-410X(97)00072-8
25. Edlmayr, J., Niespodziana, K., Linhart, B., Focke-Tejkl, M., Westritschnig, K., Scheiblhofer, S., et al. (2009). A combination vaccine for allergy and rhinovirus infections based on rhinovirus-derived surface protein VP1 and a nonallergenic peptide of the major timothy grass pollen allergen Phl p 1. J. Immunol. 182, 6298-6306. doi: 10.4049/jimmunol.0713622
26. Feldmann, M., and Easten, A. (1971). The relationship between antigenic structure and the requirement for thymus-derived cells in the immune response. J. Exp. Med. 134, 103-119. doi: 10.1084/jem.134.1.103
27. Focke, M., Mahler, V., Ball, T., Sperr, W. R., Majlesi, Y., Valent, P., et al. (2001). Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination. FASEB J. 15, 2042-2044. doi: 10.1096/fj.01-0016fje
28. Focke, M., Swoboda, I., Marth, K., and Valenta, R. (2010). Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity. Clin. Exp. Allergy 40, 385-397. doi: 10.1111/j.1365-2222.2009.03443.x
29. Focke-Tejkl, M., Weber, M., Niespodziana, K., Neubauer, A., Huber, H., Henning, R., et al. (2015). Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy. J. Allergy Clin. Immunol. 135, 1207-1217.e11. doi: 10.1016/j.jaci.2014.09.012
30. Forsbach, A., Nemorin, J. G., Volp, K., Samulowitz, U., Montino, C., Muller, C., et al. (2007). Characterization of conserved viral leader RNA sequences that stimulate innate immunity through TLRs. Oligonucleotides 17, 405-417. doi: 10.1089/oli.2007.0098
31. Fuenmayor, J., Godia, F., and Cervera, L. (2017). Production of virus-like particles for vaccines. N. Biotechnol. 39, 174-180. doi: 10.1016/j.nbt.2017.07.010
32. Ganglberger, E., Barbara, S., Scholl, I., Wiedermann, U., Baumann, S., Hafner, C., et al. (2001). Monovalent fusion proteins of IgE mimotopes are safe for therapy of type I allergy. FASEB J. 15, 2524-2526. doi: 10.1096/fj.00-0888fje
33. Gao, J., Wang, Y., Liu, Z., and Wang, Z. (2010). Phage display and its application in vaccine design. Ann. Microbiol. 60, 13-19. doi: 10.1007/s13213-009-0014-7
34. Gerstmayr, M., Ilk, N., Schabussova, I., Jahn-Schmid, B., Egelseer, E. M., Sleytr, U. B., et al. (2007). A novel approach to specific allergy treatment: the recombinant allergen-S-layer fusion protein rSbsC-bet v 1 matures dendritic cells that prime Th0/Th1 and IL-10-producing regulatory T cells. J. Immunol. 179, 7270-7275. doi: 10.4049/jimmunol.179.11.7270
35. Hazebrouck, S., Oozeer, R., Adel-Patient, K., Langella, P., Rabot, S., Wal, J. M., et al. (2006). Constitutive delivery of bovine-lactoglobulin to the digestive tracts of gnotobiotic mice by engineered Lactobacillus casei. Appl. Environ. Microbiol. 72, 7460-7467. doi: 10.1128/aem.01032-06
36. Hogenesch, H. (2012). Mechanism of immunopotentiation and safety of aluminum adjuvants. Front. Immunol. 3:406. doi: 10.3389/fimmu.2012.00406
37. Hu, S., Kong, J., Sun, Z., Han, L., Kong, W., and Yang, P. (2011). Heterologous protein display on the cell surface of lactic acid bacteria mediated by the s-layer protein. Microb. Cell Fact. 10:86. doi: 10.1186/1475-2859-10-86
38. Huibregtse, I. L., Snoeck, V., de Creus, A., Braat, H., de Jong, E. C., van Deventer, S. J. H., et al. (2007). Induction of ovalbumin-specific tolerance by oral administration of Lactococcus lactis secreting ovalbumin. Gastroenterology 133, 517-528. doi: 10.1053/j.gastro.2007.04.073
39. Hynonen, U., and Palva, A. (2013). Lactobacillus surface layer proteins: structure, function and applications. Appl. Microbiol. Biotechnol. 97, 5225-5243. doi: 10.1007/s00253-013-4962-2
40. Ilaria, P., Francesca, L.-S., and Paola, M. (2016). "Therapeutic approaches in allergic diseases, "in Immune Rebalancing, ed. D. Boraschi (Cambridge, MA: Academic Press), 85-103. doi: 10.1016/b978-0-12-803302-9.00005-1
41. Ilk, N., Schumi, C. T., Bohle, B., Egelseer, E. M., and Sleytr, U. B. (2011). Expression of an endotoxin-free S-layer/allergen fusion protein in gram-positive Bacillus subtilis 1012 for the potential application as vaccines for immunotherapy of atopic allergy. Microb. Cell Fact. 10:6. doi: 10.1186/1475-2859-10-6
42. Ilk, N., Vollenkle, C., Egelseer, E. M., Breitwieser, A., Sleytr, U. B., and Sara, M. (2002). Molecular characterization of the S-layer gene, sbpA, of Bacillus sphaericus CCM 2177 and production of a functional S-layer fusion protein with the ability to recrystallize in a defined orientation while presenting the fused allergen. Appl. Environ. Microbiol. 68, 3251-3260. doi: 10.1128/AEM.68.7.3251-3260.2002
43. Jafari, N., and Abediankenari, S. (2016). Phage particles as vaccine delivery vehicles: concepts, applications and prospects. Asian Pac. J. Cancer Prev. 16, 8019-8029. doi: 10.7314/apjcp.2015.16.18.8019
44. Jahn-Schmid, B., Graninger, M., Glozik, M., Kupcu, S., Ebner, C., Unger, F. M., et al. (1996). Immunoreactivity of allergen (Bet v 1) conjugated to crystalline bacterial cell surface layers (S-layers). Immunotechnology 2, 103-113. doi: 10.1016/1380-2933(96)00041-3
45. Jahn-Schmid, B., Siemann, U., Zenker, A., Bohle, B., Messner, P., Unger, F. M., et al. (1997). Bet v 1, the major birch pollen allergen, conjugated to crystalline bacterial cell surface roteins, expands allergen-specific T cells of the Th1/Th0 phenotype in vitro by induction of IL-12. Int. Immunol. 9, 1867-1874. doi: 10.1093/intimm/9.12.1867
46. Jegerlehner, A., Storni, T., Lipowsky, G., Schmid, M., Pumpens, P., and Bachmann, M. F. (2002a). Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation. Eur. J. Immunol. 32, 3305-3314
47. Jegerlehner, A., Tissot, A., Lechner, F., Sebbel, P., Erdmann, I., Kundig, T., et al. (2002b). A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine 20, 3104-3112
48. Jensen-Jarolim, E., Leitner, A., Kalchhauser, H., Zurcher, A., Ganglberger, E., Bohle, B., et al. (1998). Peptide mimotopes displayed by phage inhibit antibody binding to bet v 1, the major birch pollen allergen, and induce specific IgG response in mice. FASEB J. 12, 1635-1642. doi: 10.1096/fasebj.12.15.1635
49. Jepson, C. D., and March, J. B. (2004). Bacteriophage lambda is a highly stable DNA vaccine delivery vehicle. Vaccine 22, 2413-2419. doi: 10.1016/j.vaccine.2003.11.065
50. Johansen, P., Senti, G., Martinez Gomez, J. M., Storni, T., Beust, B. R., Wuthrich, B., et al. (2005). Toll-like receptor ligands as adjuvants in allergen-specific immunotherapy. Clin. Exp. Allergy 35, 1591-1598. doi: 10.1111/j.1365-2222.2005.02384.x
51. Karimi, K., Inman, M. D., Bienenstock, J., and Forsythe, P. (2009). Lactobacillus reuteri-induced regulatory T cells protect against an allergic airway response in mice. Am. J. Respir. Crit. Care Med. 179, 186-193. doi: 10.1164/rccm.200806-951OC
52. Klimek, L., Bachmann, M. F., Senti, G., and Kundig, T. M. (2014). Immunotherapy of type-1 allergies with virus-like particles and CpG-motifs. Expert Rev. Clin. Immunol. 10, 1059-1067. doi: 10.1586/1744666X.2014.924854
53. Knittelfelder, R., Riemer, A. B., and Jensen-Jarolim, E. (2009). Mimotope vaccination-from allergy to cancer. Expert Opin. Biol. Ther. 9, 493-506. doi: 10.1517/14712590902870386
54. Kruisselbrink, A., Heijne Den Bak-Glashouwer, M. J., Havenith, C. E., Thole, J. E., and Janssen, R. (2001). Recombinant Lactobacillus plantarum inhibits house dust mite-specific T-cell responses. Clin. Exp. Immunol. 126, 2-8. doi: 10.1046/j.1365-2249.2001.01642.x
55. Kündig, T., Senti, G., Schnetzler, G., Wolf, C., Prinzvavricka, B., Fulurija, A., et al. (2006). Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J. Allergy Clin. Immunol. 117, 1470-1476. doi: 10.1016/j.jaci.2006.01.040
56. Larsen, J. N., Broge, L., and Jacobi, H. (2016). Allergy immunotherapy: the future of allergy treatment. Drug Discov. Today 21, 26-37. doi: 10.1016/j.drudis.2015.07.010
57. Luzar, J., Molek, P., Šilar, M., Korošec, P., Košnik, M., Štrukelj, B., et al. (2016a). Identification and characterization of major cat allergen Fel d 1 mimotopes on filamentous phage carriers. Mol. Immunol. 71, 176-183. doi: 10.1016/j.molimm.2016.02.004
58. Luzar, J., Štrukelj, B., and Lunder, M. (2016b). Phage display peptide libraries in molecular allergology: from epitope mapping to mimotope-based immunotherapy. Allergy 71, 1526-1532. doi: 10.1111/all.12965
59. Manzano-Szalai, K., Thell, K., Willensdorfer, A., Weghofer, M., Pfanzagl, B., Singer, J., et al. (2014). Adeno-associated virus-like particles as new carriers for b-cell vaccines: testing immunogenicity and safety in BALB/c mice. Viral Immunol. 27, 438-448. doi: 10.1089/vim.2014.0059
60. Marschan, E., Kuitunen, M., Kukkonen, K., Poussa, T., Sarnesto, A., Haahtela, T., et al. (2008). Probiotics in infancy induce protective immune profiles that are characteristic for chronic low-grade inflammation. Clin. Exp. Allergy 38, 611-618. doi: 10.1111/j.1365-2222.2008.02942.x
61. Marth, K., Breyer, I., Focke-Tejkl, M., Blatt, K., Shamji, M. H., Layhadi, J., et al. (2013). A nonallergenic birch pollen allergy vaccine consisting of hepatitis pres-fused bet v 1 peptides focuses blocking IgG toward IgE epitopes and shifts immune responses to a tolerogenic and Th1 phenotype. J. Immunol. 190, 3068-3078. doi: 10.4049/jimmunol.1202441
62. Marth, K., Focke-Tejkl, M., Lupinek, C., Valenta, R., and Niederberger, V. (2014). Allergen peptides, recombinant allergens and hypoallergens for allergen-specific immunotherapy. Curr. Treat. Options Allergy 1, 91-106. doi: 10.1007/s40521-013-0006-5
63. May, R. J., Beenhouwer, D. O., and Scharff, M. D. (2003). Antibodies to keyhole limpet hemocyanin cross-react with an epitope on the polysaccharide capsule of Cryptococcus neoformans and other carbohydrates: implications for vaccine development. J. Immunol. 171, 4905-4912. doi: 10.4049/jimmunol.171.9.4905
64. Moingeon, P., de Taisne, C., and Almond, J. (2002). Delivery technologies for human vaccines. Br. Med. Bull. 62, 29-44. doi: 10.1093/bmb/62.1.29
65. Moldaver, D., and Larché, M. (2011). Immunotherapy with peptides. Allergy 66, 784-791. doi: 10.1111/j.1398-9995.2011.02610.x
66. Mowat, A. M. (2003). Anatomical basis of tolerance and immunity to intestinal antigens. Nat. Rev. Immunol. 3, 331-341. doi: 10.1038/nri1057
67. Mrkic, I., Minic, R., Bulat, T., Aradska, J., Atanaskovic-Markovic, M., Drakulic, B., et al. (2016). Modulation of the specific immune response in Balb/c mice by intranasal application of recombinant H1D2 chimera. J. Chem. Technol. Biotechnol. 92, 1328-1335. doi: 10.1002/jctb.5127
68. Niederberger, V., Neubauer, A., Gevaert, P., Zidarn, M., Worm, M., Aberer, W., et al. (2018). Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen vaccine BM32. J. Allergy Clin. Immunol. doi: 10.1016/j.jaci.2017.09.052 [Epub ahead of print]
69. Niespodziana, K., Focke-Tejkl, M., Linhart, B., Civaj, V., Blatt, K., Valent, P., et al. (2011). A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS. J. Allergy Clin. Immunol. 127, 1562-1570.e6. doi: 10.1016/j.jaci.2011.02.004
70. Ohkouchi, K., Kawamoto, S., Tatsugawa, K., Yoshikawa, N., Takaoka, Y., Miyauchi, S., et al. (2012). Prophylactic effect of Lactobacillus oral vaccine expressing a Japanese cedar pollen allergen. J. Biosci. Bioeng. 113, 536-541. doi: 10.1016/j.jbiosc.2011.11.025
71. Petrovsky, N. (2015). Comparative safety of vaccine adjuvants: a summary of current evidence and future needs. Drug Saf. 38, 1059-1074. doi: 10.1007/s40264-015-0350-4
72. Quigley, B. R., Hatkoff, M., Thanassi, D. G., Ouattara, M., Eichenbaum, Z., and Scott, J. R. (2009). A foreign protein incorporated on the tip of T3 pili in Lactococcus lactis elicits systemic and mucosal immunity. Infect. Immun. 78, 1294-1303. doi: 10.1128/iai.01037-09
73. Raha, A. R., Varma, N. R., Yusoff, K., Ross, E., and Foo, H. L. (2005). Cell surface display system for Lactococcus lactis: a novel development for oral vaccine. Appl. Microbiol. Biotechnol. 68, 75-81. doi: 10.1007/s00253-004-1851-8
74. Rakonjac, J., Bennett, N. J., Spagnuolo, J., Gagic, D., and Russel, M. (2011). Filamentous bacteriophage: biology, phage display and nanotechnology applications. Curr. Issues Mol. Biol. 13, 51-76
75. Repa, A., Grangette, C., Daniel, C., Hochreiter, R., Hoffmann-Sommergruber, K., Thalhamer, J., et al. (2003). Mucosal co-application of lactic acid bacteria and allergen induces counter-regulatory immune responses in a murine model of birch pollen allergy. Vaccine 22, 87-95. doi: 10.1016/s0264-410x(03)00528-0
76. Rigaux, P., Daniel, C., Hisbergues, M., Muraille, E., Hols, P., Pot, B., et al. (2009). Immunomodulatory properties of Lactobacillus plantarum and its use as a recombinant vaccine against mite allergy. Allergy 64, 406-414. doi: 10.1111/j.1398-9995.2008.01825.x
77. Roehnisch, T., Then, C., Nagel, W., Blumenthal, C., Braciak, T., Donzeau, M., et al. (2014). Phage idiotype vaccination: first phase I/II clinical trial in patients with multiple myeloma. J. Transl. Med. 12:119. doi: 10.1186/1479-5876-12-119
78. Saxena, M., Van, T. T., Baird, F. J., Coloe, P. J., and Smooker, P. M. (2013). Pre-existing immunity against vaccine vectors-friend or foe? Microbiology 159(Pt 1), 1-11. doi: 10.1099/mic.0.049601-0
79. Schabussova, I., and Wiedermann, U. (2008). Lactic acid bacteria as novel adjuvant systems for prevention and treatment of atopic diseases. Curr. Opin. Allergy Clin. Immunol. 8, 557-564. doi: 10.1097/ACI.0b013e328317b88b
80. Schmitz, N., Dietmeier, K., Bauer, M., Maudrich, M., Utzinger, S., Muntwiler, S., et al. (2009). Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy. J. Exp. Med. 206, 1941-1955. doi: 10.1084/jem.20090199
81. Scholl, I., Wiedermann, U., Forster-Waldl, E., Ganglberger, E., Baier, K., Boltz-Nitulescu, G., et al. (2002). Phage-displayed Bet mim 1, a mimotope of the major birch pollen allergen Bet v 1, induces B cell responses to the natural antigen using bystander T cell help. Clin. Exp. Allergy 32, 1583-1588. doi: 10.1046/j.1365-2222.2002.01527.x
82. Schwarzer, M., Repa, A., Daniel, C., Schabussova, I., Hrncir, T., Pot, B., et al. (2011). Neonatal colonization of mice with Lactobacillus plantarum producing the aeroallergen Bet v 1 biases towards Th1 and T-regulatory responses upon systemic sensitization. Allergy 66, 368-375. doi: 10.1111/j.1398-9995.2010.02488.x
83. Senti, G., Johansen, P., Haug, S., Bull, C., Gottschaller, C., Müller, P., et al. (2009). Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Clin. Exp. Allergy 39, 562-570. doi: 10.1111/j.1365-2222.2008.03191.x
84. Siskind, G. W., Paul, W. E., and Benacerraf, B. (1966). Studies on the effect of the carrier molecule on antihapten antibody synthesis. I. Effect of carrier on the nature of the antibody synthesized. J. Exp. Med. 123, 673-688. doi: 10.1084/jem.123.4.673
85. Sleytr, U. B., Schuster, B., Egelseer, E.-M., and Pum, D. (2014). S-layers: principles and applications. FEMS Microbiol. Rev. 38, 823-864. doi: 10.1111/1574-6976.12063
86. Souza, A. P., Haut, L., Reyes-Sandoval, A., and Pinto, A. R. (2005). Recombinant viruses as vaccines against viral diseases. Braz. J. Med. Biol. Res. 38, 509-522. doi: 10.1590/S0100-879X2005000400004
87. Steidler, L., Neirynck, S., Huyghebaert, N., Snoeck, V., Vermeire, A., Goddeeris, B., et al. (2003). Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat. Biotechnol. 21, 785-789. doi: 10.1038/nbt840
88. Suurmond, J., Stoop, J. N., Rivellese, F., Bakker, A. M., Huizinga, T. W., and Toes, R. E. (2014). Activation of human basophils by combined toll-like receptor-and FcγRI-triggering can promote Th2 skewing of naive T helper cells. Eur. J. Immunol. 44, 386-396. doi: 10.1002/eji.201343617
89. Szalai, K., Jensen-Jarolim, E., and Pali-Scholl, I. (2008). Vaccination strategies based on the mimotope concept. G. Ital. Dermatol. Venereol. 143, 95-104
90. Trombert, A. (2015). Recombinant lactic acid bacteria as delivery vectors of heterologous antigens: the future of vaccination? Benef. Microbes 6, 313-324. doi: 10.3920/bm2014.0068
91. Tscheppe, A., and Breiteneder, H. (2017). Recombinant allergens in structural biology, diagnosis, and immunotherapy. Int. Arch. Allergy Immunol. 172, 187-202. doi: 10.1159/000464104
92. Valenta, R., Campana, R., Focke-Tejkl, M., and Niederberger, V. (2016). Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: lessons from the past and novel mechanisms of action for the future. J. Allergy Clin. Immunol. 137, 351-357. doi: 10.1016/j.jaci.2015.12.1299
93. Valenta, R., Campana, R., and Niederberger, V. (2017). Recombinant allergy vaccines based on allergen-derived B cell epitopes. Immunol. Lett. 189, 19-26. doi: 10.1016/j.imlet.2017.04.015
94. Valenta, R., Vrtala, S., Focke-Tejkl, M., Bugajska, S., Ball, T., Twardosz, A., et al. (1999). Genetically engineered and synthetic allergen derivatives: candidates for vaccination against type I allergy. Biol. Chem. 380, 815-824. doi: 10.1515/BC.1999.101
95. van Houten, N. E., Henry, K. A., Smith, G. P., and Scott, J. K. (2010). Engineering filamentous phage carriers to improve focusing of antibody responses against peptides. Vaccine 28, 2174-2185. doi: 10.1016/j.vaccine.2009.12.059
96. van Houten, N. E., Zwick, M. B., Menendez, A., and Scott, J. K. (2006). Filamentous phage as an immunogenic carrier to elicit focused antibody responses against a synthetic peptide. Vaccine 24, 4188-4200. doi: 10.1016/j.vaccine.2006.01.001
97. van Roosmalen, M. L., Kanninga, R., El Khattabi, M., Neef, J., Audouy, S., Bosma, T., et al. (2006). Mucosal vaccine delivery of antigens tightly bound to an adjuvant particle made from food-grade bacteria. Methods 38, 144-149. doi: 10.1016/j.ymeth.2005.09.015
98. Wagachchi, D., Tsai, J.-Y. C., Chalmers, C., Blanchett, S., Loh, J. M. S., and Proft, T. (2018). PilVax-a novel peptide delivery platform for the development of mucosal vaccines. Sci. Rep. 8:2555. doi: 10.1038/s41598-018-20863-7
99. Wyszynska, A., Kobierecka, P., Bardowski, J., and Jagusztyn-Krynicka, E. K. (2015). Lactic acid bacteria-20 years exploring their potential as live vectors for mucosal vaccination. Appl. Microbiol. Biotechnol. 99, 2967-2977. doi: 10.1007/s00253-015-6498-0
100. Yepes-Nunez, J. J., Fiocchi, A., Pawankar, R., Cuello-Garcia, C. A., Zhang, Y., Morgano, G. P., et al. (2016). World allergy organization-mcmaster university guidelines for allergic disease prevention (GLAD-P): vitamin D. World Allergy Organ. J. 9:17. doi: 10.1186/s40413-016-0108-1
101. Young, R. (1992). Bacteriophage lysis: mechanism and regulation. Microbiol. Rev. 56, 430-481
102. Zadravec, P., Štrukelj, B., and Berlec, A. (2015a). Heterologous surface display on lactic acid bacteria: non-GMO alternative? Bioengineered 6, 179-183. doi: 10.1080/21655979.2015.1040956
103. Zadravec, P., Štrukelj, B., Berlec, A., and Björkroth, J. (2015b). Improvement of LysM-mediated surface display of designed ankyrin repeat proteins (DARPins) in recombinant and nonrecombinant strains of Lactococcus lactis and Lactobacillus species. Appl. Environ. Microbiol. 81, 2098-2106. doi: 10.1128/aem.03694-14
104. Zeltins, A. (2013). Construction and characterization of virus-like particles: a review. Mol. Biotechnol. 53, 92-107. doi: 10.1007/s12033-012-9598-4
105. Zieglmayer, P., Focke-Tejkl, M., Schmutz, R., Lemell, P., Zieglmayer, R., Weber, M., et al. (2016). Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy. EBioMedicine 11, 43-57. doi: 10.1016/j.ebiom.2016.08.022